(19)
(11) EP 3 252 079 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
09.09.2020 Bulletin 2020/37

(45) Mention of the grant of the patent:
29.07.2020 Bulletin 2020/31

(21) Application number: 17169315.3

(22) Date of filing: 05.04.2007
(51) International Patent Classification (IPC): 
C07K 16/40(2006.01)
A61P 9/10(2006.01)
 A61K 39/395(2006.01)
A61P 27/02(2006.01)

(54)

ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTP-BETA) AND USES THEREOF

AN DIE HUMANE PROTEINTYROSINPHOSPHATASE-BETA (HPTP-BETA) BINDENDE ANTIKÖRPER UND ANWENDUNGEN DAVON

ANTICORPS SE LIANT À LA PROTÉINE TYROSINE PHOSPHATASE BÉTA HUMAINE (HPTP-BETA) ET LEURS UTILISATIONS

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

(30) Priority: 07.04.2006 US 790506 P
09.05.2006 US 798896 P

(43) Date of publication of application:
06.12.2017 Bulletin 2017/49

(62) Application number of the earlier application in accordance with Art. 76 EPC:
11155518.1 / 2371865
07735408.2 / 2004697

(73) Proprietor: Aerpio Therapeutics LLC
Cincinnati, OH 45242 (US)

(72) Inventors:
  • Rotello, Rocco Jamie
    Lebanon, OH 45036 (US)
  • Peters, Kevin
    Cincinnati, OH 45243 (US)
  • Davis, Michael Glenn
    Lebanon, OH 45036 (US)

(74) Representative: Avidity IP 
Broers Building Hauser Forum 21 JJ Thomson Avenue
Cambridge CB3 0FA
Cambridge CB3 0FA (GB)


(56) References cited: : 
WO-A1-00/65085
 US-A1- 2004 077 065
   
  • KRUEGER N X ET AL: "STRUCTURAL DIVERSITY AND EVOLUTION OF HUMAN RECEPTOR-LIKE PROTEIN TYROSINE PHASPHATASES", EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, WILEY, DE, vol. 9, no. 10, 1 October 1990 (1990-10-01), pages 3241-3252, XP002032773, ISSN: 0261-4189
  • MUELLER SABINE ET AL: "Receptor protein tyrosine phosphatase zeta as a therapeutic target for glioblastoma therapy", EXPERT OPINION ON THERAPEUTIC TAR, INFORMA HEALTHCARE, UK, vol. 8, no. 3, 1 June 2004 (2004-06-01), pages 211-220, XP009093419, ISSN: 1472-8222, DOI: 10.1517/14728222.8.3.211
  • Kimberly A Neely ET AL: "Commentary Ocular Neovascularization Clarifying Complex Interactions", , 1 September 1998 (1998-09-01), XP055414182, Retrieved from the Internet: URL:http://ajp.amjpathol.org/article/S0002 -9440(10)65607-6/pdf [retrieved on 2017-10-10]
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).